Extrapyramidal diseases. Ⅰ.Formation of basal ganglia *Corpus striatum:/caudate nucleus \ neostriatum \lentiform/putamen nucleus / \lentiform/putamen.

Slides:



Advertisements
Similar presentations
Extrapyramidal disorder and movement disorder
Advertisements

Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Cortically OriginatedMovement Cortically Originated Movement I. Motor Tract (corticospinal tractus) Extrapyramidal System (basal ganglia) Cerebellum Praxis.
Diagnosis and Management of Parkinson’s Disease
Pharmacology of Drugs Used in Parkinson’s Disease Jose Paciano B.T. Reyes, FPNA ASMPH January 27, 2011.
Parkinson’s Disease (PD)
An Overview of Conventional and Experimental Treatments
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
运动障碍疾病 Movement Disorders
Idiopathic parkinson’s disease (IPD)
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
EXTRAPYRAMIDAL SYSTEM DISORDERS BASAL GANGLION DYSFUNCTION BASAL GANGLION DYSFUNCTION.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
BASAL GANGLIA PHARMACOLOGY Sammy Case & Matt Vreugde
Initial Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease By Nik Sanyal.
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Wooooo!. Give me 3 causes of gait abnormality:  Parkinson’s disease, Huntington’s disease, Parkinson plus syndromes: Multiple System Atrophy, Lewy Body.
Basal ganglia & cerebellar pathology
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Dr. Kleyn Department of Geriatric Medicine SVCMC
Neuromuscular Disorders Brenda P. Johnson, PhD, RN.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Making Things Happen - 2 Motor Disorders How Your Brain Works - Week 7 Dr. Jan Schnupp HowYourBrainWorks.net.
Parkinson’s Disease superKAT :).
Brainstem and Basal Ganglia
By Prof. Hanan Hagar Pharmacology unit Medical College.
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Basal Nuclei Connections And Clinical Correlations.
Movement Disorders K. Zárubová. Movement disorders MD - abnornal involuntary movements dysfunction of basal ganglia (anatomically) dysfunction of extrapyramidal.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Brain Motor Control Lesson 20. Hierarchical Control of Movement n Association cortices & Basal Ganglia l strategy : goals & planning l based on integration.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
A neurology primer. Idiopathic Parkinson Disease (also referred to as primary or classical Parkinson disease)  is a progressive neurodegenerative disorder.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Drugs in parkinsonism ilos
Extrapyramidal pathway
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
PARKINSON’S DISEASE Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Brain Mechanisms of Movement Lecture 19. Hierarchical Control of Movement n Association cortices & Basal Ganglia l strategy : goals & planning l based.
1 EXTRAPYRAMIDAL DISORDERS = Movement disorders = Degenerative disease.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
Direct motor pathway Corticospinal pathway. Motor Units – Large Versus Small Text Fig
 DEFINITION: It includes all fibers that can influence the motor end plate activity and do not pass in the pyramidal tract.
Direct motor pathway Corticospinal pathway.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinson Disease Parkinson disease is an idiopathic, slowly progressive, degenerative disorder characterized by resting tremor, stiffness (rigidity),
MOVEMENT DISORDERS.
DRUGS FOR PARKINSONISM
Drugs of Anti-Parkinson’s disease
Parkinson's disease KRZYSZTOF NICPOŃ.
EXTRAPYRAMIDAL SYSTEM DISORDERS
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Basal ganglia It is a collection of grey matter deeply in each
Neurodegenerative diseases
Presentation transcript:

Extrapyramidal diseases

Ⅰ.Formation of basal ganglia *Corpus striatum:/caudate nucleus \ neostriatum \lentiform/putamen nucleus / \lentiform/putamen nucleus / nucleus\globus pallidus- paleostriatum nucleus\globus pallidus- paleostriatum *Red nucleus *Substantia nigra *Subthalamic nucleus

Ⅱ Function Regulation of voluntary motor activity

Ⅲ.clinical features 1.Poverty of movement-hypertonia syndrome position: substantia nigra ;globus pallidus position: substantia nigra ;globus pallidus ex : Parkinson ’ s disease ex : Parkinson ’ s disease 2.Increasing of movement-hypotonia syndrome position: caudate nucleus ;putamen nucleus position: caudate nucleus ;putamen nucleus ex : Chorea minor ex : Chorea minor

Parkinson’s Disease

Ⅰ.Definition It is also called paralysis agitans. It is a slowly progressive degeneration disease of the extrapyramidal system. It is characterized by tremor 、 rigidity 、 bradykinesia 、 abnormal gait and attitude.

Ⅱ.Etiology and Pathogenesis 1.age:>40years old \ 2.Environmental factors :MPTP degeneration of DA neurons of DA neurons 3.Genetic factor / (>50%)

Ⅲ.Pathology and biochemical pathology 1.Pathology (1)Macroscopic changes: no special changes (2)Microscopic changes:widespread cellular degeneration, in substantia nigra, degeneration, in substantia nigra, Lewy’s body Lewy’s body

2.Biochemical pathology HVA HVA  tyrosine ↓ dopadecar ↓ decomposition tyrosine ↓ dopadecar ↓ decomposition hydroxylase - boxylase ↑MAO,COMT hydroxylase - boxylase ↑MAO,COMT Levo-tyrosine →→→→ Levodopa →→→→ dopamine ↓ ↓ ↘ ↓ ↘ Caudate nucleus ←←←←←←←←←↓ ↘ Caudate nucleus ←←←←←←←←←↓ ↘ ↙ Substantia nigra- Ach ↑ ↙ Substantia nigra- Ach ↑ putamen ↙ corpus striatum path ↓ putamen ↙ corpus striatum path ↓ nucleus ↓ nucleus ↓ clinical features clinical features

Ⅳ.Clinical Features 1.tremor:usually first occur(60-70%) “pill-rolling” “pill-rolling” static tremor : the tremor is present static tremor : the tremor is present when the patient is at rest. When the when the patient is at rest. When the patient is nervous,the tremor patient is nervous,the tremor increase. When the patient move increase. When the patient move voluntarily or sleep, the tremor is voluntarily or sleep, the tremor is suppressed or disappears entirely. suppressed or disappears entirely.

2.rigidity Cog-wheel rigidity lead-pipe rigidity

3.bradykinesia (1).Voluntary movements are reduced (2).Masked face (3).micrographia

4.Abnormal gait and attitude (1).generalized flexion (2).festinating gait

5.Other symptoms (1).autonomic disturbances : hypersteatosis:oily face; hypersteatosis:oily face; hyperhidrosis; constipation hyperhidrosis; constipation sphincter disturbance is rare sphincter disturbance is rare (2).mental symptoms: dementia ;depression (3).dysarthria(4).salivation

Ⅴ.Diagnosis 1.It occurs in old people,the onset is insidious and progress gradually. 2.Clinical features: tremor 、 rigidity 、 bradykinesia 、 abnormal attitude and gait.

Ⅵ.Differential Diagnosis 1.Secondary parkinson’s disease (Parkinsonism) (Parkinsonism) (1).infection: encephalitis lethargica (2).poisoning: CO,Mn (3).drugs (4).cerebral arteriosclerosis (5).trauma

2.Others (1).Depression (2).Essential tremor (3).multiple system atrophy: OPCA (4).thyrotoxicosis,alcoholism.

Ⅶ.Treatment 1.Drug treatment (1).anticholinergic drugs Artane 2mg tid po;kemadrin 2.5mg tid po Side-effects: retention of urine; enlarged pupil; enlarged pupil; hypohidrosis; confusion hypohidrosis; confusion Contraindications:hypertrophy of prostrate glaucoma glaucoma

(2).amantadine: 50mg tid po Side-effects :insomnia ; confusion; hallucination hallucination Contraindications: epileptic ;hepatic and renal dysfunction and renal dysfunction

(3)Levodopa L-dopa + dopadecarboxylase L-dopa + dopadecarboxylase inhibitor(DCI) inhibitor(DCI) Ex : Madopar ; Sinemet Ex : Madopar ; Sinemet

Side-effects 1.Peripheral side-effects: nauea ;vomiting nauea ;vomiting Postural hypotension; Postural hypotension; cardiac arrhythmia cardiac arrhythmia

2.Central side-effects (1).motor fluctuation a.End of dose deterioration b.on-off phenomenon (2).dyskinesia a.peak-dose dyskinesia b.Biphasic dyskinesia c.Dystonia (3).mental symptoms:confusion;hallucination

(4)Dopamine receptor stimulant drug: bromocriptine (5)monoamine oxidase B inhibitor (6)COMT inhibitor 2.Surgical treatment 3.Cell transplantation and gene therapy 4.Rehabilitation treatment

C horea minor C horea minor

Ⅰ.Definition It is also called Sydenham chorea. It is a common nervous system manifestation of rheumatic fever, it often occurs in children. It is characterized by involuntarily choretic movements 、 hypotonia 、 weakness 、 mental symptoms.

Ⅱ Etiology Infection of A hemolytic streptococus

Ⅲ.Clinical features 1.onset:5-15 years old ; F>M; subacute or insidious or insidious 2.Choretic movements 3.Muscular tension and power are reduced 4.Mental symptoms 5.Symptoms of rheumatic fever: cardiac disease; fever; WBC↑;rheumatic disease; fever; WBC↑;rheumatic arthritis; subcutaneous nodule ;blood arthritis; subcutaneous nodule ;blood sedimentation↑;ASO↑ sedimentation↑;ASO↑

Ⅳ.Diagnosis 1.The age of onset 2.Clinical features 3.Symptoms of rheumatic fever

Ⅴ.Treatment 1.Etiological treatment 1.Etiological treatment Penicillin days Penicillin days 2.Symptomatic treatment 2.Symptomatic treatment Valii; luminal; chlorpromazine Valii; luminal; chlorpromazine

Hepatolenticular Degeneration (HLD)

Ⅰ.Definition It is also called Wilson’s disease.It is an autosomal recessive inheritant disease caused by copper metabolic disorder. The affected areas mainly are liver and basal ganglia. It is characterized by progressive extrapyramidal symptoms 、 cirrhosis of the liver 、 mental symptoms and K-F ring.

Ⅱ.Etiology and Pathogenesis  Copper  +  2 globulins  ceruloplasmin  enzyme   bile,urine,sweet   bile,urine,sweet    liver  cirrhosis of the liver   liver  cirrhosis of the liver abnormal   basal ganglia  extrapyramidal deposition symptoms  kidney  renal dysfunction  kidney  renal dysfunction  cornea  K-F ring  cornea  K-F ring

Ⅲ.Pathology Degeneration : liver Degeneration : liver basal ganglia basal ganglia kidney kidney cornea cornea

Ⅳ.Clinical Features 1.nervous symptoms 1.nervous symptoms (1)extrapyramidal symptoms: choretic (1)extrapyramidal symptoms: choretic action;tremor;rigidity;bradykinesia action;tremor;rigidity;bradykinesia (2)mental symptoms:intelligent deficiency (2)mental symptoms:intelligent deficiency 2.symptoms of cirrhosis of the liver 2.symptoms of cirrhosis of the liver 3.K-F ring: 95% 3.K-F ring: 95% 4.others: renal dysfunction 4.others: renal dysfunction

Ⅴ.Investigation 1.ceruloplasmin of serum:↓ g/L 2.copper oxidase activity:↓

Ⅵ.Diagnosis 1.the symptoms of liver and extrapyramidal system. 2.the levels of CP and copper oxidase activity are reduced. 3.K-F ring of cornea 4.positive family history

Ⅶ.Treatment 1.low-copper diet 2.drug treatment first -choice: D-penicillamine 3.symptomatic therapy 4.surgical treatment